GSE176008 pyridoxine 4 v 1 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE176008_pyridoxine_4_v_1_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE176008_pyridoxine_4_v_1_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE176008_pyridoxine_4_v_1_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE176008_pyridoxine_4_v_1_human_up.

Results found

Linked to

 

Label

Description

 

Gene

DnaJ heat shock protein family (Hsp40) member A3

Gene

cell division cycle 20

Gene

joining chain of multimeric IgA and IgM

Gene

annexin A1

Gene

proliferating cell nuclear antigen

Gene

LSM5 homolog, U6 small nuclear RNA and mRNA degradation associated

Gene

E2F transcription factor 2

Gene

thiol methyltransferase 1A

Gene

heat shock protein family A (Hsp70) member 8

Gene

IKAROS family zinc finger 1

  • Gene

    DnaJ heat shock protein family (Hsp40) member A3


  • Gene

    cell division cycle 20


  • Gene

    joining chain of multimeric IgA and IgM



  • Gene

    proliferating cell nuclear antigen


  • Gene

    LSM5 homolog, U6 small nuclear RNA and mRNA degradation associated


  • Gene

    E2F transcription factor 2


  • Gene

    thiol methyltransferase 1A


  • Gene

    heat shock protein family A (Hsp70) member 8


  • Gene

    IKAROS family zinc finger 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.